Orforglipron

What Is Orforglipron?

Orforglipron is a once-daily oral medication that activates the GLP-1 receptor, the same target as injectable drugs like semaglutide, but is built as a small molecule rather than a peptide. This allows it to be taken without the food and water restrictions needed by oral peptide-based GLP-1 drugs.

Orforglipron was discovered by Chugai Pharmaceutical and licensed by Eli Lilly in 2018. It became the first small-molecule GLP-1 receptor agonist to successfully complete Phase 3 trials, and Lilly has filed a New Drug Application for obesity.

What Orforglipron Is Being Researched For

• Body Weight in Obesity

  The Phase 3 ATTAIN-1 trial found all three tested doses met the primary endpoint of superior weight reduction versus placebo, with the highest dose producing an average loss of 12.4% at 72 weeks.^[1]

• Type 2 Diabetes

  The Phase 3 ACHIEVE-1 trial found average A1C reductions of 1.3% to 1.6% at 40 weeks compared with placebo.^[2]

• Obesity With Type 2 Diabetes and Weight Maintenance

  ATTAIN-2 studied people with obesity and type 2 diabetes and found 10.5% average weight reduction at the highest dose alongside A1C improvement. ATTAIN-MAINTAIN separately examined weight maintenance after switching from injectable GLP-1 therapy.^[3]

How Orforglipron Works

• Activating the GLP-1 Receptor as a Small Molecule

  Research points to orforglipron binding and activating the GLP-1 receptor, increasing insulin release, reducing glucagon, slowing digestion, and signaling fullness through a non-peptide structure that survives digestion.^[1][2]

• No Food or Water Restrictions

  The small-molecule design allows orforglipron to be taken without the fasting and limited-water conditions needed by oral peptide-based GLP-1 drugs.

• A Safety Profile Consistent With Injectable GLP-1 Drugs

  Across its Phase 3 program, overall safety and tolerability were described as consistent with injectable GLP-1 medications, with gastrointestinal symptoms among the most common side effects.^[3]

Reconstitution and Handling

Orforglipron is administered as an oral capsule and does not require reconstitution. It should be stored according to product labeling, generally in a cool, dry place away from direct light.

Key Takeaways

Orforglipron is the first small-molecule, non-peptide GLP-1 receptor agonist to succeed through Phase 3 trials in both diabetes and obesity, avoiding the digestive fragility that limits oral peptide-based GLP-1 drugs. It remains investigational pending FDA review despite its completed trials and regulatory filing.

Frequently Asked Questions

Sources and Research

1. Wharton S, et al. Once-Daily Oral Orforglipron for the Treatment of Obesity. N Engl J Med. 2025.
2. Rosenstock J, et al. Oral Orforglipron in Type 2 Diabetes: The Phase 3 ACHIEVE-1 Trial. 2025.
3. Garvey WT, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025.